BioPharm International's January 2021 issue, Volume 34, Number 1
Biopharma Gets Back to “New Normal” Business
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
Compensation Does Not Necessarily Align with Job Satisfaction
Essential bio/pharma employees show hard work and dedication can pay off, for patients.
Can Cell and Gene Therapies Achieve Their Full Potential?
Advances in development, data management, and automation, and closer collaboration with contract development and manufacturing partners, are pushing more therapies closer to commercialization.
Cultivating a Synthetic Biology-Based Approach to Improving Cell Culture
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
EASY: a Disruptive mAb Purification Process to Reduce Cost of Goods
The development of an innovative purification process simplifies downstream processing for biologics.
The Importance of Process Intensification and PAT for Achieving Real-Time Release
Creativity and collaboration are required to overcome complex method development challenges.
Accelerating Technology Adoption to Track the Cold Chain
Packaging and transporting large quantities of COVID-19 vaccines pose challenges for the cold chain.
Using Protein Characterization to Support Regulatory Submissions
Clear understanding of what exactly the biomolecule entails is essential.
Supporting the Industry During a Pandemic
Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.
Pandemic Control to Shape Biopharma in 2021
The incoming administration faces key decisions on drug testing and access as well as vaccine distribution challenges.
Ensuring Vaccine Supply Meets Need
Shutting down the COVID-19 pandemic requires a global, selfless effort.
Now is the Time to Update the Quality Technical Agreement
Updating the quality technical agreement will clarify any expectations and limitations, says Siegfried Schmitt, vice president, Technical at Parexel.
